Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients

Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients - Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044811

Enrollment

Registered

2021-07-09

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients aged 20 years or older with PS 0-2 at the time of consent (2) Patients with advanced or recurrent non-small cell lung cancer that is not curatively resectable (3) Patients with evaluable lesions by RECIST (version 1.1) (4) Patients who are scheduled to receive combination therapy including ipilimumab and nivolumab. (5) Patients who have been fully informed about the contents of this clinical study and have given their free written consent. (5) Patients who have been fully informed about the contents of this clinical study and have given their free written consent.

Exclusion criteria

Exclusion criteria: (1) Patients with active multiple cancers (hormonal therapy for prostate cancer and breast cancer is acceptable) (2)Patients with a history of treatment with systemic chemotherapy or immune checkpoint inhibitors (However, molecularly targeted cancer drugs for patients with positive driver gene mutations and postoperative adjuvant chemotherapy for patients with postoperative recurrence are acceptable) (3)Other patients who are judged inappropriate by the physician in charge.

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Countries

Japan

Contacts

Public ContactYuki Katayama

Kyoto Prefectural University of Medicine Pulmonary Medicine

ktym2487@koto.kpu-m.ac.jp0752515513

Outcome results